VAP® Lipid Panel Highlighted in Eight Scientific Presentations at 2013 American Heart Association Scientific Sessions
The VAP® Lipid Panel from Atherotech Diagnostics Lab has been involved in numerous research projects in 2013 that support the important clinical utility of testing with the VAP Lipid Panel for comprehensive and accurate cardiovascular risk assessment.
At this year’s American Heart Association (AHA) Scientific Sessions, The VAP (Vertical Auto Profile) Lipid Panel is utilized in eight independent investigator-initiated scientific presentations: seven poster abstract presentations and one oral abstract presentation. Highly respected researchers Parag H. Joshi, M.D.; Seth S. Martin, M.D.; Peter P. Toth, M.D.; Kristopher J. Swiger, M.D.; Mohammed Al-hijji, M.D.; and Raoul Manalac, M.D., are presenting findings during the conference.
Poster presentations 13843 and 14026 examine HDL subfractions, remnant lipoprotein subfractions and their relationship with cardiovascular events from a meta-analysis of the Framingham Offspring Study and Jackson Heart Study. Both will be presented from 3:00 p.m. to 4:30 p.m. on Monday, November 18, 2013, in Hall F, Core 2. Poster presentations 17313 and 17492 examine an investigational, cholesterol-lowering drug targeting the PCSK9 gene. Both will be presented on Tuesday, November 19, from 3:00 p.m. to 4:30 p.m. in Hall F, Core 2.
Three additional poster presentations — 16020, 18557, and 18730 — detail studies by Johns Hopkins researchers using Atherotech’s Very Large Database of Lipids (VLDL) and the VAP Lipid Panel. The current VLDL dataset includes more than 1.4 million data points representing unique individuals. Researchers in the VLDL presentations examined cholesterol subclasses, lipid phenotypes and the triglyceride/HDL cholesterol ratio.
Atherotech recently entered into a strategic research collaboration with the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. The partnership pairs Atherotech’s VLDL dataset with Johns Hopkins’ world-class cardiac research capabilities.
The final abstract presentation — 11909 from the Best of AHA Specialty Conferences — studies the connection between remnant lipoprotein cholesterol and mortality after acute myocardial infarction in the TRIUMPH Prospective Multi-Center Registry.
Furthermore, Atherotech will provide conference participants with their own VAP+ Lipid Panel to experience how important it is to accurately identify cardiovascular disease risk, personalize treatment and improve heart health outcomes. Atherotech representatives will be available to discuss the VAP+ Lipid Panel in booth #2308. Because LDL is directly measured, fasting is not required.
To arrange interviews with any of these presenters or other Atherotech medical experts who will be in attendance and can provide outside comment on these and other sessions, please call 720-231-9990 or e-mail email@example.com. All research results are embargoed until the time they are presented during the conference. All times listed are Central Standard Time. Please refer to the American Heart Association for embargo policies pertaining to presentations at the Scientific Sessions.
The VAP Lipid Panel is covered by most insurance plans and is widely available to patients and their clinicians in the U.S. For information on the VAP Lipid Panel and Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real patient cases and lipidology commentary may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.twitter.com/Atherotech, on Facebook at www.facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.
About Atherotech Diagnostics Lab & the VAP®+ Lipid Panel
Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP+ utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy HeartTM, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.
Note to Editors: All research results are embargoed until the time of presentation
Dan Snyders, 303-623-1190 x230
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here